아시아태평양의 일반의약품(OTC) : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the Asia-Pacific over-the-Counter (OTC) drugs market size in 2026 is estimated at USD 45.97 billion, growing from 2025 value of USD 42.48 billion with 2031 projections showing USD 68.24 billion, growing at 8.22% CAGR over 2026-2031.

This report is Segmented by Product Type (Cough, Cold, and Flu Medicines, Analgesics, Dermatology OTC, and More), Formulation Type (Tablets & Capsules, Liquids & Syrups, and More), Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drugstores, and More), and Country (China, Japan, India, and More). The Market Forecasts are Provided in Terms of Value (USD).

Asia-Pacific Over-the-counter (OTC) Drugs Market Trends and Insights

High Penetration in Emerging APAC Markets with Increasing OTC Approvals

Emerging economies remove bureaucratic bottlenecks, enabling faster brand rollouts and improving safety oversight through harmonized digital submissions. The Philippines' new payment portal has trimmed approval lead-times from months to weeks, prompting multinationals to prioritize Asia-first launches over traditional Western rollouts. Rising investment inflows in Vietnam and Indonesia facilitate technology transfer that equips domestic firms with improved formulation skills. Superior pharmacist training and upgraded retail footprints nurture consumer trust in self-medication, boosting the Asia-Pacific Over-the-Counter (OTC) Drugs market across lower-income cohorts.

Rx-to-OTC Switches by Multinational & Local Pharma

Structured switch programs, notably in Japan, have shifted allergy sprays and proton-pump inhibitors to OTC status, enlarging access while securing premium pricing for proven actives. Sato Pharmaceutical's once-daily Nazoncek nasal spray exemplifies how timely switches create fresh categories, generate exclusivity windows and protect brand equity. Local manufacturers exploit cultural nuance by tailoring flavor, dosage and pack size, running neck-and-neck with global giants as the Asia-Pacific Over-the-Counter (OTC) Drugs market widens.

Low Consumer Awareness & Risk of Drug Abuse

Limited health literacy in rural zones elevates misuse risks, prompting authorities to restrict pack sizes and enforce warning labels that dampen market uptake. Companies must allocate budget to education campaigns in multiple languages, raising cost-of-sales ratios within the Asia-Pacific Over-the-Counter (OTC) Drugs market. Pharmacies hesitate to widen assortments when liability fears loom, and traditional medicine beliefs sometimes clash with dosage norms.

Other drivers and restraints analyzed in the detailed report include:

1. Rapid Growth of Self-Medication Among Ageing Population
2. Cross-Border E-Pharmacy Platforms Accelerating Regional Access
3. Stringent, Non-Harmonised OTC Regulations Across APAC

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Vitamins, Minerals & Supplements anchored the Asia-Pacific Over-the-Counter (OTC) Drugs market with a 29.02% slice in 2025, reflecting persistent demand for immune, bone and metabolic support. Sleep Aids, however, are scaling at a 9.88% CAGR as urban screen exposure and shift-work cycles disrupt circadian rhythms. The Asia-Pacific Over-the-Counter (OTC) Drugs market size for Sleep Aids is forecast to reach a high-single-digit share by 2031, aided by melatonin gummies that combine natural positioning with palatable formats. Cough, Cold & Flu preparations maintain steady baseline volumes tied to pollution peaks, and analgesics cater to mobility-focused seniors and fitness-minded millennials. Dermatology OTCs capitalize on K-beauty influence, while probiotics and antacids address diet-driven digestive issues across the region's diverse cuisines.

Extended shelf space for premium omega-3, collagen and joint formulas reflects growing affordability among middle-income households. Retailers deploy end-cap promotions for immunity bundles, cross-merchandising with functional beverages to reinforce preventive care behavior. E-pharmacy search analytics reveal surging keyword queries for "natural sleep" and "herbal stress relief," informing targeted SKU introductions. Regulatory scrutiny around weight-loss aids persists, yet demand endures through herbal claims compliance. Ophthalmic OTCs gain ground as screen-induced dry-eye cases climb, confirming the Asia-Pacific Over-the-Counter (OTC) Drugs market's adaptability to lifestyle shifts.

Complete Report Scope:

• By Product Type
  • Cough, Cold & Flu Medicines
  • Analgesics
    • Non-opioid
    • Opioid-based
  • Dermatology OTC
    • Topical Antifungals
    • Acne Treatments
  • Gastrointestinal OTC
    • Antacids & Anti-ulcerants
    • Laxatives & Antidiarrheals
  • Vitamins, Minerals & Supplements (VMS)
  • Weight-loss & Dietary Products
  • Ophthalmic OTC
  • Sleep Aids
• By Formulation Type
  • Tablets & Capsules
  • Liquids & Syrups
  • Topicals (Creams, Ointments, Gels)
  • Sprays & Inhalers
  • Gummies & Chewables
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies & Drugstores
  • Convenience & Grocery Stores
  • Online Pharmacies & Marketplaces
• By Country
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of South-East Asia

List of Companies Covered in this Report:

1. Abbott Laboratories
2. Aurobindo Pharma
3. Bayer
4. Cipla
5. Dabur India Ltd.
6. Dr. Reddy's Laboratories
7. Haleon PLC
8. Johnson & Johnson
9. Mitsuya Holdings
10. Nichiban Co. Ltd.
11. Otsuka Holdings Co.
12. Prestige Consumer Healthcare
13. Procter & Gamble
14. PT Kalbe Farma Tbk
15. Reckitt Benckiser Group
16. Rohto Pharmaceutical Co.
17. Sanofi
18. Taisho Pharmaceutical Holdings
19. Takeda Pharmaceutical Co.
20. Zuellig Pharma

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 High Penetration In Emerging APAC Markets with Increasing OTC Approvals
  • 4.2.2 Rx-To-OTC Switches by Multinational & Local Pharma
  • 4.2.3 Rapid Growth of Self-Medication Among Ageing Population
  • 4.2.4 Cross-Border E-Pharmacy Platforms Accelerating Regional Access
  • 4.2.5 AI-Based Self-Diagnosis Tools Driving Impulse OTC Purchases
• 4.3 Market Restraints
  • 4.3.1 Low Consumer Awareness & Risk of Drug Abuse
  • 4.3.2 Stringent, Non-Harmonised OTC Regulations Across APAC
  • 4.3.3 API Supply-Chain Concentration Creating Stock-Out Risks
  • 4.3.4 Growth Of Counterfeit OTC Products on E-Commerce Sites
• 4.4 Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Porter's Five Forces Analysis
  • 4.6.1 Threat of New Entrants
  • 4.6.2 Bargaining Power of Buyers/Consumers
  • 4.6.3 Bargaining Power of Suppliers
  • 4.6.4 Threat of Substitute Products
  • 4.6.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product Type
  • 5.1.1 Cough, Cold & Flu Medicines
  • 5.1.2 Analgesics
    • 5.1.2.1 Non-opioid
    • 5.1.2.2 Opioid-based
  • 5.1.3 Dermatology OTC
    • 5.1.3.1 Topical Antifungals
    • 5.1.3.2 Acne Treatments
  • 5.1.4 Gastrointestinal OTC
    • 5.1.4.1 Antacids & Anti-ulcerants
    • 5.1.4.2 Laxatives & Antidiarrheals
  • 5.1.5 Vitamins, Minerals & Supplements (VMS)
  • 5.1.6 Weight-loss & Dietary Products
  • 5.1.7 Ophthalmic OTC
  • 5.1.8 Sleep Aids
• 5.2 By Formulation Type
  • 5.2.1 Tablets & Capsules
  • 5.2.2 Liquids & Syrups
  • 5.2.3 Topicals (Creams, Ointments, Gels)
  • 5.2.4 Sprays & Inhalers
  • 5.2.5 Gummies & Chewables
• 5.3 By Distribution Channel
  • 5.3.1 Hospital Pharmacies
  • 5.3.2 Retail Pharmacies & Drugstores
  • 5.3.3 Convenience & Grocery Stores
  • 5.3.4 Online Pharmacies & Marketplaces
• 5.4 By Country
  • 5.4.1 China
  • 5.4.2 Japan
  • 5.4.3 India
  • 5.4.4 Australia
  • 5.4.5 South Korea
  • 5.4.6 Rest of South-East Asia

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global-level Overview, Market-level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
  • 6.3.1 Abbott Laboratories
  • 6.3.2 Aurobindo Pharma
  • 6.3.3 Bayer AG
  • 6.3.4 Cipla Ltd.
  • 6.3.5 Dabur India Ltd.
  • 6.3.6 Dr. Reddy's Laboratories
  • 6.3.7 Haleon PLC
  • 6.3.8 Johnson & Johnson
  • 6.3.9 Mitsuya Holdings
  • 6.3.10 Nichiban Co. Ltd.
  • 6.3.11 Otsuka Holdings Co.
  • 6.3.12 Prestige Consumer Healthcare
  • 6.3.13 Procter & Gamble Co.
  • 6.3.14 PT Kalbe Farma Tbk
  • 6.3.15 Reckitt Benckiser Group PLC
  • 6.3.16 Rohto Pharmaceutical Co.
  • 6.3.17 Sanofi SA
  • 6.3.18 Taisho Pharmaceutical Holdings
  • 6.3.19 Takeda Pharmaceutical Co.
  • 6.3.20 Zuellig Pharma

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment